Description
Blincyto (blinatumomab) is a prescription medicine used to treat certain types of acute lymphoblastic leukemia (ALL), particularly B-cell precursor ALL that is relapsed or refractory (has returned or not responded to previous treatment). It is also approved for minimal residual disease (MRD)-positive ALL, where small traces of leukemia remain after treatment.
Reviews
There are no reviews yet.